##ikh spinocerebellar ataxia 3. cerebellum. 2016 ; 15 : 518 – 25. https : / / d rh, gendron tf, heckman mg, et al. toward allele - specific tar - o i. o r g / 1 0. 1 0 0 7 / s 1 2 3 1 1 - 0 1 5 - 0 7 1 9 - z. geting therapy and pharmacodynamic marker for spinocerebellar 35. dennis a - g, almaguer - mederos le, raul r - a, roberto r - l, ataxia type 3. sci transl med. 2020. https : / / doi. org / 1 0. 1 1 2 6 / s c i t r luis v - p, dany c - a, et al. redox imbalance associates with clinia n s l m e d. a b b 7 0 8 6. cal worsening in spinocerebellar ataxia type 2. oxid med cell 21. hubener - schmid j, kuhlbrodt k, peladan j, faber j, santana longev. 2021 ; 2021 : 9875639. https : / / doi. org / 1 0. 1 1 5 5 / 2 0 2 1 / 9 8 7 5 mm, hengel h, et al. polyglutamine - expanded ataxin - 3 : a 6 3 9. target engagement marker for spinocerebellar ataxia type 3 in 36. de assis am, saute jam, longoni a, haas cb, torrez vr, broperipheral blood. mov disord. 2021 ; 36 : 2675 – 81. https : / / doi. org / chier aw, et al. peripheral oxidative stress biomarkers in spino1 0. 1 0 0 2 / m d s. 2 8 7 4 9. cerebellar ataxia type 3 / machado - joseph disease. front neurol. 22. berger m, garcia - moreno h, hubener - schmid j, schaprian t, 2017 ; 8 : 485. https : / / doi. org / 1 0. 3 3 8 9 / f n e u r. 2 0 1 7. 0 0 4 8 5. wegner p, elter t, et al. progression of biological markers in 37. torres - ramos y, mont